co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are

Company profile
Ticker
CODX
Exchange
Website
CEO
Dwight Egan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
DNA Logix, Inc. • Idaho Molecular, Inc. • Advanced Conceptions, Inc. ...
CODX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
31 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results
10 Aug 23
DEF 14A
Definitive proxy
20 Jul 23
8-K
Departure of Directors or Certain Officers
16 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Co-Diagnostics, Inc. Reports First Quarter 2023 Financial Results
11 May 23
EFFECT
Notice of effectiveness
7 Apr 23
8-K
Changes in Registrant's Certifying Accountant
5 Apr 23
CORRESP
Correspondence with SEC
4 Apr 23
Transcripts
CODX
Earnings call transcript
2023 Q2
10 Aug 23
CODX
Earnings call transcript
2023 Q1
11 May 23
CODX
Earnings call transcript
2022 Q4
16 Mar 23
CODX
Earnings call transcript
2022 Q3
11 Nov 22
CODX
Earnings call transcript
2022 Q2
11 Aug 22
CODX
Earnings call transcript
2022 Q1
13 May 22
CODX
Earnings call transcript
2021 Q4
24 Mar 22
CODX
Earnings call transcript
2021 Q3
12 Nov 21
CODX
Earnings call transcript
2021 Q2
13 Aug 21
CODX
Earnings call transcript
2021 Q1
14 May 21
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.83 mm | 13.83 mm | 13.83 mm | 13.83 mm | 13.83 mm | 13.83 mm |
Cash burn (monthly) | (no burn) | 6.02 mm | 4.00 mm | 4.55 mm | 1.74 mm | 1.13 mm |
Cash used (since last report) | n/a | 18.13 mm | 12.04 mm | 13.71 mm | 5.23 mm | 3.41 mm |
Cash remaining | n/a | -4.30 mm | 1.79 mm | 124.46 k | 8.60 mm | 10.42 mm |
Runway (months of cash) | n/a | -0.7 | 0.4 | 0.0 | 5.0 | 9.2 |
Institutional ownership, Q2 2023
14.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 7 |
Closed positions | 18 |
Increased positions | 7 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 4.14 bn |
Total shares | 4.39 mm |
Total puts | 42.10 k |
Total calls | 40.70 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.78 mm | $1.98 bn |
Renaissance Technologies | 653.70 k | $726.00 k |
BLK Blackrock | 506.51 k | $562.23 mm |
Geode Capital Management | 302.16 k | $335.39 mm |
Bridgeway Capital Management | 272.90 k | $302.92 mm |
BK Bank Of New York Mellon | 145.62 k | $161.64 mm |
STT State Street | 100.65 k | $111.72 mm |
First Trust Advisors | 81.18 k | $90.11 mm |
MNGPF Man | 74.10 k | $82.25 mm |
Koss-Olinger Consulting | 65.07 k | $72.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jun 23 | James B Nelson | RSU Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 150,000 |
12 Jun 23 | Serbin Richard S | RSU Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 150,000 |
12 Jun 23 | Ted Murphy | RSU Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 150,000 |
12 Jun 23 | Eugene Durenard | RSU Common Stock | Grant | Acquire A | No | No | 0 | 70,000 | 0.00 | 150,000 |
23 May 23 | Eugene Durenard | Common Stock | Grant | Acquire A | No | No | 0 | 18,333 | 0.00 | 55,000 |
23 May 23 | Eugene Durenard | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 18,333 | 0.00 | 80,000 |
News
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
21 Sep 23
HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2
14 Aug 23
Co-Diagnostics Q2 EPS $(0.31) Misses $(0.24) Estimate, Sales $200.00K Miss $500.00K Estimate
10 Aug 23
Earnings Scheduled For August 10, 2023
10 Aug 23
Press releases
Co-Diagnostics, Inc. to Participate in the 2023 UHCA/UCAL Fall Convention & Expo on Sept 27-28
27 Sep 23
Co-Diagnostics, Inc. to Participate in 6th ACTC Conference in Skiathos, Greece
22 Sep 23
Co-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21
21 Sep 23
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 11-13, 2023
7 Sep 23
Co-Diagnostics, Inc. Appoints Chief Regulatory Affairs Officer
29 Aug 23